As filed with the U.S. Securities and Exchange Commission on November 15, 2024

Registration No. 333-      

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM S-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

180 Life Sciences Corp.

(Exact name of registrant as specified in itscharter)

3000 El Camino Real, Bldg. 4, Suite 200
Palo Alto, CA 94306
(650) 507-0669

(Address, including zip code, and telephonenumber, including area code, of registrant’s principal executive offices)

Mr. Blair Jordan
Chief Executive Officer
180 Life Sciences Corp.
3000 El Camino Real, Bldg. 4, Suite 200
Palo Alto, CA 94306
(650) 507-0669

(Name, address, including zip code, and telephonenumber, including area code, of agent for service)

Copies to:

David M. Loev, Esq.

John S. Gillies, Esq.

The Loev Law Firm, PC

6300 West Loop South, Suite 280

Bellaire, Texas 77401

Telephone: (713) 524-4110

Approximate date of commencementof proposed sale to the public: From time to time after this registration statement becomes effective.

If any of the securities beingregistered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, checkthe following box: ☒

If this Form is filed to registeradditional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list theSecurities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effectiveamendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registrationstatement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effectiveamendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registrationstatement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whetherthe registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerginggrowth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company,indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financialaccounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

The registrant hereby amends this registrationstatement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment whichspecifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of theSecurities Act of 1933 or until the registration statement shall become effective on such date as the Securities and Exchange Commission,acting pursuant to said Section 8(a), may determine.

The information containedin this prospectus is not complete and may be changed. The selling stockholder may not sell these securities until the registration statementfiled with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not solicitingan offer to buy these securities in any state where the offer or sale is not permitted.

SUBJECT TO COMPLETION,DATED NOVEMBER 15, 2024

PRELIMINARY PROSPECTUS

1,900,138 Shares of Common Stock

This prospectus relates solelyto the offer and sale from time to time of up to an aggregate of 1,900,138 shares of our common stock, par value $0.0001 per share, of180 Life Sciences Corp., a Delaware corporation (the “Company,” “we,” “our” or“us”), by the selling stockholder identified in this prospectus (the “Selling Stockholder”). Theshares of common stock being registered for resale hereunder consist of: 1,900,138 shares of common stock issuable upon the exercise ofthe October 2024 Warrants (as defined herein), acquired by the Selling Stockholder, pursuant to an Inducement Agreement (as defined herein)entered into between us and the Selling Stockholder (the “Warrants,” and all of the shares of common stock issuableupon exercise of the Warrants, the “Shares”).

Each of the Warrants are exercisableat an exercise price of $1.50. We are not selling any common stock under this prospectus and will not receive any of the proceeds fromthe sale of the Shares by the Selling Stockholder. However, if all of the Warrants that are covered by this prospectus are exercised forcash, we may receive proceeds of up to approximately $2,850,207. We intend to use those proceeds, if any, for operationalizing and developingour recently acquired Technology Gaming Platform, and general corporate and legal expenses. We will bear all other costs, expenses andfees in connection with the registration of the Shares. The Selling Stockholder will bear all commissions and discounts, if any, attributableto the sales of Shares.

The Selling Stockholder mayoffer such Shares from time to time as it may determine through public or private transactions or through other means described in thesection entitled “Plan of Distribution” beginning on page 18 of this prospectus, at prevailing market prices,at prices related to prevailing market prices or at privately negotiated prices. This prospectus does not necessarily mean that the SellingStockholder will offer or sell the Shares. We cannot predict when or in what amounts the Selling Stockholder may sell any of the Sharesoffered by this prospectus. Any Shares subject to resale hereunder will have been issued by us and acquired by the Selling Stockholderprior to any resale of such Shares pursuant to this prospectus. Because all of the Shares offered under this prospectus are being offeredby the Selling Stockholder, we cannot currently determine the price or prices at which the Shares may be sold under this prospectus.

Our common stock is tradedon the Nasdaq Capital Market (“Nasdaq”) under the symbol “ATNF”. On November 14, 2024, thelast reported sale price for our common stock as reported on Nasdaq was $2.68 per share.

INVESTING IN OUR SECURITIESINVOLVES SUBSTANTIAL RISKS. SEE THE SECTION TITLED “RISK FACTORS” BEGINNING ON PAGE 7 OF THIS PROSPECTUS TO READABOUT FACTORS YOU SHOULD CONSIDER BEFORE BUYING OUR SECURITIES.

NEITHER THE SECURITIESAND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACYOR ACCURACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

The date of this prospectus is              , 2024.

TABLE OF CONTENTS

Our logo and some of our trademarksand tradenames are used in this prospectus. This prospectus also includes trademarks, tradenames and service marks that are the propertyof others. Solely for convenience, trademarks, tradenames and service marks referred to in this prospectus may appear without the ®,™ and SM symbols. References to our trademarks, tradenames and service marks are not intended to indicate in any way that we willnot assert to the fullest extent under applicable law our rights or the rights of the applicable licensors if any, nor that respectiveowners to other intellectual property rights will not assert, to the fullest extent under applicable law, their rights thereto. We donot intend the use or display of other companies’ trademarks and trade names to imply a relationship with, or endorsement or sponsorshipof us by, any other companies.

The market data and certainother statistical information used throughout this prospectus are based on independent industry publications, reports by market researchfirms or other independent sources that we believe to be reliable sources; however, we have not commissioned any of the market or surveydata that is presented in this prospectus. Industry publications and third-party research, surveys and studies generally indicate thattheir information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completenessof such information. We are responsible for all of the disclosures contained in this prospectus, and we believe these industry publicationsand third-party research, surveys and studies are reliable, provided that we have not commissioned any such information. While we arenot aware of any misstatements regarding any third-party information presented in this prospectus, their estimates, in particular, asthey relate to projections, involve numerous assumptions, are subject to risks and uncertainties, and are subject to change based on variousfactors, including those discussed under the section entitled “Risk Factors” of this prospectus. These and otherfactors could cause our future performance to differ materially from our assumptions and estimates. Some market and other data includedherein, as well as the data of competitors as they relate to 180 Life Sciences Corp., is also based on our good faith estimates.

Unless the context requiresotherwise, references to the “Company,” “we,” “us,” “our,”“180 Life”, “180LS” and “180 Life Sciences Corp.” refer specifically to 180 LifeSciences Corp. and its consolidated subsidiaries. References to “KBL” refer to the Company prior to the November 6,2020 Business Combination.

In addition, unless the contextotherwise requires and for the purposes of this prospectus only:

Effective on December 19,2022 at 12:01 a.m. Eastern Time, we affected a 1-for-20 reverse stock split of our then outstanding common stock, with any fractionalshares rounded up to the nearest whole share. Effective on February 28, 2024 at 12:01 a.m. Eastern Time, we affected a 1-for 19 reversestock split of our then outstanding common stock with any fractional shares rounded up to the nearest whole share.

In connection with the reversesplits, all outstanding options, warrants, and other securities entitling their holders to purchase or otherwise receive shares of commonstock were adjusted, as required by the terms of each security. The number of shares available to be awarded under the Company’sequity incentive plans were also appropriately adjusted. Following the reverse splits, the par value of the common stock remained unchangedat $0.0001 par value per share. The reverse splits did not change the authorized number of shares of common stock or preferred stock.

The effects of the reversestock splits have been retroactively reflected throughout this prospectus.

About This Prospectus

This prospectus is part ofa registration statement on Form S-1 that we filed with the SEC. Under this registration statement, the Selling Stockholder may, fromtime to time, sell the shares of common stock offered by it as described in this prospectus. We will not receive any proceeds from thesale by such Selling Stockholder of the Shares offered by it as described in this prospectus. We will not receive any proceeds from thesale of Shares pursuant to this prospectus, except with respect to amounts received by us upon the exercise of the Warrants for cash,if any.

Neither we nor the SellingStockholder have authorized anyone to provide you with any information or to make any representations other than those contained in thisprospectus or any applicable prospectus supplement or any free writing prospectus prepared by or on behalf of us or to which we have referredyou. Neither we nor the Selling Stockholder take responsibility for, and can provide no assurance as to the reliability of, any otherinformation that others may give you. Neither we nor the Selling Stockholder will make an offer to sell these securities in any jurisdictionwhere the offer or sale is not permitted. You should not assume that the information contained in this prospectus is accurate as of anydate other than the date of this prospectus. Our business, financial condition, results of operations and prospects may have changed sincethat date.

We may also provide a prospectussupplement or post-effective amendment to the registration statement to add information to, or update or change information containedin, this prospectus. You should read both this prospectus and any applicable prospectus supplement or post-effective amendment to theregistration statement together with the additional information to which we refer you in the sections of this prospectus entitled “Incorporationby Incorporation” and “Where You Can Find More Information.”

Risk Factors

Investing in shares of ourcommon stock involves a high degree of risk. Before making an investment decision, you should carefully consider and evaluate the risksdescribed in the “Risk Factors” section in our most recent Annual Report on Form 10-K, as well as any updates to thoserisk factors in our subsequent Quarterly Reports on Form 10-Q, and below, together with all of the other information appearing in or incorporatedby reference into this prospectus, before deciding whether to purchase any of the common stock being offered. The risks described in thesedocuments are not the only ones we face, but those that we consider to be material. There may be other unknown or unpredictable economic,business, competitive, regulatory or other factors that could have material adverse effects on our future results. Our business, financialcondition or results of operations could be materially adversely affected by any of these risks. The trading price of shares of our commonstock could decline due to any of these risks, and you may lose all or part of your investment. Please also read carefully the sectionentitled “Cautionary Note Regarding Forward-Looking Statements.”

Sales of substantialamounts of our common stock by the selling stockholder, or the perception that these sales could occur, could adversely affect theprice of our common stock.

The sale by the selling stockholderof a significant number of shares of common stock could have a material adverse effect on the market price of our common stock. In addition,the perception in the public markets that the selling stockholder may sell all or a portion of its shares as a result of theregistration of such shares for resale pursuant to this prospectus could also in and of itself have a material adverse effecton the market price of our common stock. We cannot predict the effect, if any, that market sales of those shares of common stock or theavailability of those shares of common stock for sale will have on the market price of our common stock.

We currently havean illiquid and volatile market for our common stock, and the market for our common stock is and may remain illiquid and volatile in thefuture.

We currently have a highlysporadic, illiquid and volatile market for our common stock, which market is anticipated to remain sporadic, illiquid and volatile inthe future. During the last 52 weeks our common stock has traded as high as $17.75 per share and as low as $1.16 per share. The marketprice of our common stock may continue to be highly volatile and subject to wide fluctuations. Our financial performance, government regulatoryaction, tax laws, interest rates, and market conditions in general could have a significant impact on the future market price of our commonstock.

Our common stock is listedon the Nasdaq Capital Market under the symbol “ATNF.” Our stockprice may be impacted by factors that are unrelated or disproportionate to our operating performance. The stock markets in general haveexperienced extreme volatility that has often been unrelated to the operating performance of particular companies. These broad marketfluctuations may adversely affect the trading price of our common stock. Additionally, general economic, political and market conditions,such as recessions, inflation, war, interest rates or international currency fluctuations may adversely affect the market price of ourcommon stock. Due to the limited volume of our shares which trade, we believe that our stock prices (bid, ask and closing prices) maynot be related to our actual value, and not reflect the actual value of our common stock. You should exercise caution before making aninvestment in us.

Stock markets in general andour stock price in particular have recently experienced extreme price and volume fluctuations that have often been unrelated or disproportionateto the operating performance of those companies and our company. For example, during 2022, the closing sales prices of our common stockranged from a post-split adjusted high of $1,482.04 per share to a low of $23.56 per share, during fiscal 2023, the closing sales pricesof our common stock ranged from a high of $100.70 per share to a low of $3.21 per share and during fiscal 2024 (through the date of thisprospectus), the closing sales prices of our common stock ranged from a post-split adjusted high of $6.47 per share to a low of $1.18per share. During this time, we do not believe that we have experienced any material changes in our financial condition or results ofoperations that would explain such price volatility or trading volume; however, we have sold equity which was dilutive to existing stockholders.These broad market fluctuations may adversely affect the trading price of our securities. Additionally, these and other external factorshave caused and may continue to cause the market price and demand for our common stock to fluctuate substantially, which may limit orprevent our stockholders from readily selling their shares of our common stock and may otherwise negatively affect the liquidity of ourcommon stock.

Additionally, as a resultof the illiquidity of our common stock, investors may not be interested in owning our common stock because of the inability to acquireor sell a substantial block of our common stock at one time. Such illiquidity could have an adverse effect on the market price of ourcommon stock. In addition, a shareholder may not be able to borrow funds using our common stock as collateral because lenders may be unwillingto accept the pledge of securities having such a limited market. An active trading market for our common stock may not develop or, ifone develops, may not be sustained.

In the past, many companiesthat have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may bethe target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert ourmanagement’s attention from other business concerns, which could seriously harm our business.

The exercise of theoutstanding options and warrants, and the sale of common stock upon exercise thereof, may adversely affect the trading price of our securities.

As of the date of this prospectus,we had 22,891 shares of common stock issuable upon the exercise of outstanding stock options, with a weighted average exercise price of$61.92 per share; (a) 15,132 shares of common stock issuable upon the exercise of outstanding public warrants exercisable at an exerciseprice of $4,370.00 per share, (b) 6,748 shares of common stock issuable upon the exercise of certain outstanding private placementwarrants at an exercise price of $1,900.00 per share, (d) 6,579 shares of common stock issuable upon the exercise of certain outstandingprivate placement warrants at an exercise price of $2,850.00 per share, (e) 4,049 shares of common stock issuable upon exercise of certainoutstanding warrants to purchase shares of common stock with an exercise price of $3.23 per share, (f) 3,000,000 shares of commonstock issuable upon the exercise of warrants to purchase 3,000,000 shares of common stock with an exercise price of $1.68 per share, (g)168 shares of common stock issuable upon exercise of warrants which expire on May 2, 2025, and (h) 1,900,138 shares of common stock issuableupon exercise of the October 2024 Warrants with an exercise price of $1.50 per share. For the life of the options and warrants, the holdershave the opportunity to profit from a rise in the market price of our common stock without assuming the risk of ownership. The issuanceof shares upon the exercise of outstanding securities will also dilute the ownership interests of our existing stockholders.

The availability of theseshares for public resale, as well as any actual resales of these shares, could adversely affect the trading price of our common stock.We cannot predict the size of future issuances of our common stock pursuant to the exercise of outstanding options or warrants or conversionof other securities, or the effect, if any, that future issuances and sales of shares of our common stock may have on the market priceof our common stock. Sales or distributions of substantial amounts of our common stock (including shares issued in connection with anacquisition), or the perception that such sales could occur, may cause the market price of our common stock to decline.

In addition, the common stockissuable upon exercise/conversion of outstanding convertible securities may represent overhang that may also adversely affect the marketprice of our common stock. Overhang occurs when there is a greater supply of a company’s stock in the market than there is demandfor that stock. When this happens the price of our stock will decrease, and any additional shares which stockholders attempt to sell inthe market will only further decrease the share price. If the share volume of our common stock cannot absorb shares sold by holders ofour outstanding convertible securities, then the value of our common stock will likely decrease.

There may not be sufficientliquidity in the market for our securities in order for investors to sell their shares. The market price of our common stock may continueto be volatile.

The market price of our commonstock will likely continue to be highly volatile. Some of the factors that may materially affect the market price of our common stockare beyond our control, such as conditions or trends in the industry in which we operate or sales of our common stock. This situationis attributable to a number of factors, including the fact that we are a small company which is relatively unknown to stock analysts,stock brokers, institutional investors and others in the investment community that generate or influence sales volume, and that even ifwe came to the attention of such persons, they tend to be risk-averse and would be reluctant to follow an unproven company such as oursor purchase or recommend the purchase of our shares until such time as we became more seasoned and viable.

As a consequence, there maybe periods of several days or more when trading activity in our shares is minimal or non-existent, as compared to a mature issuer whichhas a large and steady volume of trading activity that will generally support continuous sales without an adverse effect on share price.It is possible that a broader or more active public trading market for our common stock will not develop or be sustained, or that tradinglevels will not continue. These factors may materially adversely affect the market price of our common stock, regardless of our performance.In addition, the public stock markets have experienced extreme price and trading volume volatility. This volatility has significantlyaffected the market prices of securities of many companies for reasons frequently unrelated to the operating performance of the specificcompanies. These broad market fluctuations may adversely affect the market price of our common stock.

Stockholders may bediluted significantly through our efforts to obtain financing and satisfy obligations through the issuance of additional shares of ourcommon stock.

Wherever possible, our Boardwill attempt to use non-cash consideration to satisfy obligations. In many instances, we believe that the non-cash consideration willconsist of restricted shares of our common stock or where shares are to be issued to our officers, directors and applicable consultants.Our Board of Directors has authority, without action or vote of the stockholders, but subject to Nasdaq rules and regulations (which generallyrequire stockholder approval for any transactions which would result in the issuance of more than 20% of our then outstanding shares ofcommon stock or voting rights representing over 20% of our then outstanding shares of stock, subject to certain exceptions), to issueall or part of the authorized but unissued shares of common stock. In addition, we may attempt to raise capital by selling shares of ourcommon stock, possibly at a discount to market. These actions will result in dilution of the ownership interests of existing stockholders,which may further dilute common stock book value, and that dilution may be material. Such issuances may also serve to enhance existingmanagement’s ability to maintain control of the Company because the shares may be issued to parties or entities committed to supportingexisting management.

Incorporation byReference

The SEC allows us to “incorporateby reference” into this prospectus the information in other documents that we file with it. This means that we can discloseimportant information to you by referring you to those documents. The information incorporated by reference is considered to be a partof this prospectus, and information in documents that we file later with the SEC will automatically update and supersede information containedin documents filed earlier with the SEC or contained in this prospectus. We incorporate by reference in this prospectus the documentslisted below and any future filings that we may make with the SEC under Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act priorto the termination of the offering under this prospectus; provided, however, that we are not incorporating, in each case, any documentsor information deemed to have been furnished and not filed in accordance with SEC rules:

Additionally, all documentsfiled by us with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after (i) the date of the initial registration statementof which this prospectus forms a part and prior to effectiveness of the registration statement, and (ii) the date of this prospectus andbefore the termination or completion of any offering hereunder, shall be deemed to be incorporated by reference into this prospectus fromthe respective dates of filing of such documents, except that we do not incorporate any document or portion of a document that is “furnished”to the SEC, but not deemed “filed.”

We will provide, without charge,to each person to whom a copy of this prospectus is delivered, including any beneficial owner, upon the written or oral request of suchperson, a copy of any or all of the documents incorporated by reference herein, including exhibits. Requests should be directed to: Attention:Corporate Secretary, 3000 El Camino Real, Bldg. 4, Suite 200, Palo Alto, California 94306, telephone (650) 507-0669 . The documentsincorporated by reference may be accessed on the “Investors”—”SEC Filings”—”AllSEC Filings” page of our website at www.180lifesciences.com. We do not incorporate the information on our website into thisprospectus or any supplement to this prospectus and you should not consider any information on, or that can be accessed through, our websiteas part of this prospectus or any supplement to this prospectus (other than those filings with the SEC that we specifically incorporateby reference into this prospectus or any supplement to this prospectus).

Any statement contained ina document incorporated or deemed to be incorporated by reference in this prospectus will be deemed modified, superseded or replaced forpurposes of this prospectus to the extent that a statement contained in this prospectus modifies, supersedes or replaces such statement.

Cautionary NoteRegarding Forward-Looking Statements

This prospectus contains forward-lookingstatements under federal securities laws, including within the meaning of the Private Securities Litigation Reform Act of 1995.In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,”“continue,” “could,” “estimate,” “expect,” “intend,”“may,” “ongoing,” “plan,” “potential,” “predict,”“project,” “should,” or the negative of these terms or other comparable terminology, although notall forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results, andwill not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-lookingstatements are based on information available at the time the statements are made and involve known and unknown risks, uncertainties andother factors that may cause our results, levels of activity, performance or achievements to be materially different from the informationexpressed or implied by the forward-looking statements in this prospectus, including those incorporated by reference into the sectionentitled “Risk Factors” herein.

In particular, forward-lookingstatements include, but are not limited to, any statements that are not statements of current or historical facts, such as statementsrelating to our expectations for the clinical and preclinical development, manufacturing, regulatory approval, and commercialization ofour product candidates, the accuracy of our estimates regarding expenses, future revenues and capital requirements, our ability to executeour plans to develop and market new drug products and the timing and costs of these development programs, and estimates of the sufficiencyof our existing capital resources combined with future anticipated cash flows to finance our operating requirements.

Such statements are basedon management’s current expectations and include, but are not limited to:

Any forward-looking statementsin this prospectus reflect our current views with respect to future events or to our future financial performance and involve known andunknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially differentfrom any future results, performance or achievements expressed or implied by these forward-looking statements. Given these uncertainties,you should not place undue reliance on these forward-looking statements. All forward-looking statements included herein speak only asof the date of this prospectus. All subsequent written and oral forward-looking statements attributable to us, or persons acting on ourbehalf, are expressly qualified in their entirety by the cautionary statements above. Except as required by law, we assume no obligationto update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

Use of Proceeds

We will not receive any ofthe proceeds from the sale by the Selling Stockholder of the Shares in this offering. However, if all of the Warrants that are coveredby this prospectus are exercised for cash, we may receive proceeds of up to approximately $2,850,207. We cannot predict when, or if, theWarrants will be exercised. It is possible that the Warrants may expire and may never be exercised for cash. We intend to use any proceedsfrom the exercise of the Warrants for operationalizing and developing our recently acquired Technology Gaming Platform, and general corporateand legal expenses. Our management will have broad discretion over the use of proceeds from the exercise of the Warrants.

The Selling Stockholder willpay any underwriting discounts and commissions and expenses incurred by the Selling Stockholder for brokerage, accounting, tax or legalservices or any other expenses incurred by the Selling Stockholder in disposing of the Shares. We will bear all other costs, fees andexpenses incurred in effecting the registration of the Shares covered by this prospectus, including all registration and filing fees,and fees and expenses of our counsel and our independent registered public accountants.

Dividend Policy

We have never paid or declaredany cash dividends on our common stock and do not anticipate paying cash dividends in the foreseeable future. We anticipate that we willretain all of our future earnings for use in the operation of our business and for general corporate purposes. Any determination to paydividends in the future will be at the discretion of our board of directors. Accordingly, investors must rely on sales of their commonstock after price appreciation, which may never occur, as the only way to realize any future gains on their investments.

Beneficial Ownershipof Securities

Security Ownership of Management and CertainBeneficial Owners and Management

The following table containsinformation regarding the beneficial ownership of our voting stock as of November 15, 2024 (the “Date of Determination”),held by (i) each stockholder known by us to beneficially own more than 5% of the outstanding shares of any class of voting stock;(ii) our directors; (iii) our Named Executive Officers as defined in the Summary Executive Compensation Table of our AnnualReport on Form 10-K for the year ended December 31, 2023, which is incorporated by reference herein; and (iv) all current directorsand executive officers as a group. Except where noted, all holders listed below have sole voting power and investment power over the sharesbeneficially owned by them. Unless otherwise noted, the address of each person listed below is c/o 180 Life Sciences Corp., 3000 El CaminoReal, Bldg. 4, Suite 200, Palo Alto, California 94306.

Beneficial ownership has beendetermined in accordance with Rule 13d-3 under the Exchange Act. Under this rule, certain shares may be deemed to be beneficially ownedby more than one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, sharesare deemed to be beneficially owned by a person if the person has the right to acquire shares (for example, upon exercise of an optionor warrant or upon conversion of a convertible security) within 60 days of the date as of which the information is provided. In computingthe percentage ownership of any person, the amount of shares is deemed to include the amount of shares beneficially owned by such personby reason of such acquisition rights. As a result, the percentage of outstanding shares of any person as shown in the following tabledoes not necessarily reflect the person’s actual voting power at any particular date.

Beneficial ownership as setforth below is based on our review of our record stockholders list and public ownership reports filed by certain of our stockholders,and may not include certain securities held in brokerage accounts or beneficially owned by the stockholders described below.

Change of Control

The Company is not aware ofany arrangements which may at a subsequent date result in a change of control of the Company, except that at such time as the shareholdersof the Company have approved the issuance of shares of common stock upon conversion of our 1,000,000 shares of outstanding Series B ConvertiblePreferred Stock, if ever, such shares of Series B Convertible Preferred Stock currently held by El Ray Resources, Inc., will be convertibleinto 40% of outstanding shares of common stock (subject to a maximum of 10 million shares), at the time of such stockholder approval  (66.7%of the Company’s pre-issuance outstanding shares of common stock).

Selling Stockholder

The Shares being offered bythe Selling Stockholder consist of 1,900,138 shares of common stock issuable upon the exercise of the October 2024 Common Warrants, seethe section entitled “Prospectus Summary—Warrants and Related Transactions”, above. We are registeringthe Shares in order to permit the Selling Stockholder to offer the Shares for resale from time to time.

The table below lists theSelling Stockholder and other information regarding the beneficial ownership of the shares of our common stock by the Selling Stockholder.The second column lists the number of shares of common stock beneficially owned by the Selling Stockholder, based on its ownership ofthe shares of common stock and Warrants, as of November 15, 2024, assuming exercise of the Warrants held by the Selling Stockholder onthat date, if any, without regard to any limitations on exercises. The third column lists the shares of common stock being offered bythis prospectus by the Selling Stockholder. The fourth column assumes the sale of all of the Shares offered by the Selling Stockholderpursuant to this prospectus.

Under the terms of each ofthe Warrants, the Selling Stockholder may not exercise the warrants to the extent such exercise would cause the Selling Stockholder, togetherwith its affiliates and attribution parties, to beneficially own a number of shares of common stock which would exceed 4.99%, of our thenoutstanding common stock following such exercise, excluding for purposes of such determination shares of common stock issuable upon exerciseof such Warrants which have not been exercised. The number of shares of common stock in the second and fourth columns do not reflect thislimitation.

The Selling Stockholder maysell all, some or none of their Shares in this offering. See “Plan of Distribution.”

Plan of Distribution

The Selling Stockholder andany of its pledgees, assignees, transferees and successors-in-interest may, from time to time, sell any or all of the Shares covered herebyon Nasdaq or any other stock exchange, market or trading facility on which the securities are traded or in private transactions. Thesesales may be at fixed or negotiated prices. The Selling Stockholder may use any one or more of the following methods when selling securities:

The Selling Stockholder mayalso sell the Shares under Rule 144 or any other exemption from registration under the Securities Act, if available, rather than underthis prospectus.

Broker-dealers engaged bythe Selling Stockholder may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discountsfrom the Selling Stockholder (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amountsto be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in excess of acustomary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown incompliance with FINRA Rule 2121.

In connection with the saleof the Shares or interests therein, the Selling Stockholder may enter into hedging transactions with broker-dealers or other financialinstitutions, which may in turn engage in short sales of the Shares in the course of hedging the positions they assume. The Selling Stockholdermay also sell the Shares short and deliver the Shares to close out their short positions, or loan or pledge the securities to broker-dealersthat in turn may sell the Shares. The Selling Stockholder may also enter into option or other transactions with broker-dealers or otherfinancial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financialinstitution of the Shares offered by this prospectus, which Shares such broker-dealer or other financial institution may resell pursuantto this prospectus (as supplemented or amended to reflect such transaction).

The Selling Stockholder andany broker-dealers or agents that are involved in selling the Shares may be deemed to be “underwriters” within themeaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agentsand any profit on the resale of the Shares purchased by them may be deemed to be underwriting commissions or discounts under the SecuritiesAct. The Selling Stockholder has informed us that it does not have any written or oral agreement or understanding, directly or indirectly,with any person to distribute the Shares.

We are required to pay certainfees and expenses incurred by us incident to the registration of the Shares. We have agreed to indemnify the Selling Stockholder againstcertain losses, claims, damages and liabilities, including liabilities under the Securities Act.

We agreed to keep this prospectuseffective until all of the Shares underlying the Warrants have been sold pursuant to this prospectus or Rule 144 under the SecuritiesAct or any other rule of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers ifrequired under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be soldunless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualificationrequirement is available and is complied with.

Under applicable rules andregulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in marketmaking activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to the commencementof the distribution. In addition, the Selling Stockholder will be subject to applicable provisions of the Exchange Act and the rules andregulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the common stock by the Selling Stockholderor any other person. We will make copies of this prospectus available to the Selling Stockholder and have informed it of the need to delivera copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the SecuritiesAct).

Description ofCapital Stock

Authorized Capital Stock

The following summary ofthe material terms of our capital stock is not intended to be a complete summary of the rights and preferences of such securities. Weurge you to read our Certificate of Incorporation, as amended in its entirety, for a complete description of the rights and preferencesof our securities.

As of the date of this prospectus,we have 100,000,000 authorized shares of common stock, $0.0001 par value per share and 5,000,000 shares of preferred stock, $0.0001 parvalue per share, of which 1,000,000 shares have been designated as Series A Convertible Preferred Stock (of which none are outstanding),of which one share of preferred stock has been designated as a Class C Special Voting Share, of which none are outstanding, and one shareof preferred stock has been designated as a Class K Special Voting Share, of which none are outstanding, and of which 1,000,000 shareshave been designated as Series B Convertible Preferred Stock, of which 1,000,000 shares are outstanding.

As the date of this prospectus,there were 1,976,999 shares of common stock outstanding held by 122 holders of record, and 1,000,000 shares of Series B Convertible PreferredStock issued or outstanding, held by one holder of record.

Common Stock

Except as otherwise requiredby law or as otherwise provided in any certificate of designation for any series of preferred stock, the holders of our common stock possessall voting power for the election of our directors and all other matters requiring stockholder action and will at all times vote togetheras one class on all matters submitted to a vote of our stockholders. Holders of common stock are entitled to one vote per share on mattersto be voted on by stockholders and do not have the right to cumulate votes in the election of directors.

Holders of common stock willbe entitled to receive dividends and other distributions, if any, in amounts declared from time to time by our Board of Directors in itsdiscretion out of funds legally available therefor and shall share equally on a per share basis in these dividends and distributions.

In the event of ourvoluntary or involuntary liquidation, dissolution, distribution of assets or winding-up, the holders of the common stock will be entitledto receive an equal amount per share of all of our assets of whatever kind available for distribution to stockholders, after the rightsof the holders of the preferred stock, if any, have been satisfied.

Our stockholders have no preemptiveor other subscription rights and there are no sinking fund or redemption provisions applicable to our common stock.

Our Board of Directors isdivided into two classes, with only one class of directors being elected in each year and each class generally serving a two-year term.

Preferred Stock

Our Certificate of Incorporationprovides that shares of preferred stock may be issued from time to time in one or more series. Our Board of Directors will be authorizedto fix the voting rights, if any, designations, powers, preferences, the relative, participating, optional or other special rights andany qualifications, limitations and restrictions thereof, applicable to the shares of each series. Our Board of Directors will be ableto, without stockholder approval, issue preferred stock with voting and other rights that could adversely affect the voting power andother rights of the holders of the common stock and could have anti-takeover effects. The ability of our Board of Directors to issue preferredstock without stockholder approval could have the effect of delaying, deferring or preventing a change of control of the Company or theremoval of existing management.

Series B ConvertiblePreferred Stock

The below is a summary of the rightsand preferences of the Series B Convertible Preferred Stock:

Voting Rights. Untilsuch time, if ever, as the stockholders of the Company have approved the issuance of shares of common stock upon the conversion of theSeries B Convertible Preferred Stock (“Stockholder Approval”), the Series B Convertible Preferred Stock only has rightsto vote on amendments to the Series B Designation (which are subject to the approval of a simple majority of the holders of Series B ConvertiblePreferred Stock), and the Protective Provisions, discussed below.

The Series B Preferred Stockrequire the consent of the holders of at least a majority of the issued and outstanding shares of Series B Convertible Preferred Stockto (a) increase or decrease (other than by redemption or conversion) the total number of authorized shares of Series B ConvertiblePreferred Stock of the Company; (b) adopt or authorize any new designation of any Preferred Stock or amend the Certificate of Incorporationof the Company in a manner which (i) provides any holder of common stock or preferred stock any rights upon a liquidation of theCompany which are prior and superior to those of the holders of the Series B Convertible Preferred Stock; or (ii) adversely affectthe rights, preferences and privileges of the Series B Convertible Preferred Stock; (c) effect an exchange, or create a right ofexchange, cancel, or create a right to cancel, of all or any part of the shares of another class of shares into shares of Series B ConvertiblePreferred Stock; (d) alter or change the rights, preferences or privileges of the shares of Series B Convertible Preferred Stockso as to affect adversely the shares of such series; and (e) issue any shares of Series A Preferred Stock or Series B ConvertiblePreferred Stock, other than the 1,000,000 shares of Series B Preferred Stock currently outstanding (collectively, the “ProtectiveProvisions”).

After Stockholder Approval,in addition to the above voting rights, each holder of outstanding shares of Series B Convertible Preferred Stock shall be entitled tocast the number of votes in connection with the Series B Convertible Preferred Stock shares held by such holder equal to the number ofwhole shares of common stock into which the shares of Series B Convertible Preferred Stock held by such holder are convertible as of therecord date for determining stockholders entitled to vote on such matter. Fractional votes shall not, however, be permitted and any fractionalvoting rights available on an as-converted to common stock basis (after aggregating all fractional shares into which shares of SeriesB Convertible Preferred Stock held by each holder could be converted) shall be rounded down to the nearest whole share. Except asprovided by law or by the other provisions of the Certificate of Incorporation or the Series B Designation, holders of Series B ConvertiblePreferred Stock shall vote together with the holders of common stock as a single class and there shall be no series voting.

Dividend Rights. None,except that if the Company declares a dividend or makes a distribution of cash (or any other distribution treated as a dividend underSection 301 of the Internal Revenue Code) on its common stock, each holder of Shares of Series B Convertible Preferred Stock is entitledto participate in such dividend or distribution in an amount equal to the largest number of whole shares of common stock into which allshares of Series B Convertible Preferred Stock held of record by such holder are convertible as of the record date for such dividend ordistribution or, if there is no specified record date, as of the date of such dividend or distribution. Notwithstanding the foregoing,holders shall have no right of participation in connection with dividends or distributions made to the common stock stockholders consistingsolely of shares of common stock.

Liquidation Preference.In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary (each a “LiquidationEvent”), the holders of Series B Convertible Preferred Stock are entitled to receive prior and in preference to any distributionof any of the assets of the Company to the holders of the common stock or securities junior to the Series B Convertible Preferred Stock(other than the common stock) by reason of their ownership of such stock, but after any required distribution to any holders of SeriesB Convertible Preferred Stock, an amount in cash per share of Series B Convertible Preferred Stock for each share of Series B ConvertiblePreferred Stock held by them equal to the greater of (x) one times the Stated Value; and (y) the total amount of considerationthat would have been payable on such share upon a Liquidation Event, had such share of Series B Convertible Preferred Stock been convertedinto common stock, immediately prior to such Liquidation Event (as applicable, the “Liquidation Preference”). The “StatedValue” is $17.30 per share of Series B Convertible Preferred Stock, for a total aggregate Liquidation Preference of $17,300,000.

Conversion Rights.None prior to Stockholder Approval. After Stockholder Approval, at the option of the holder(s) thereof, each share of Series B ConvertiblePreferred Stock is convertible into a number of shares of common stock of the Company as equals the Conversion Rate. The “ConversionRate” shall initially be 0.685 (or 685,000 shares in aggregate, which would represent 40% of the Company’s then outstandingshares of common stock (66.7% of the Company’s pre-issuance outstanding shares of common stock)), as equitably adjusted, as applicablefor stock splits and recapitalizations; provided that if at any time after the original issuance date of the Series B Convertible PreferredStock and prior to the Stockholder Approval Date, the Company shall actually issue any additional shares of common stock of the Company(each a “Dilutive Issuance”), the Conversion Rate shall be increased to a value equal to (x)(i) the total outstandingshares of common stock (“Total Outstanding Shares”) on the date immediately following such Dilutive Issuance,divided by (ii) 60%, minus (iii) the Total Outstanding Shares on the date immediately following such Dilutive Issuance, dividedby (y) 1,000,000, rounded to the thousands place, as equitably adjusted, as applicable for stock splits and recapitalizations (eacha “Dilutive Adjustment”); provided that in no event will the Conversion Rate be greater than ten. The effect of anychange in the Conversion Rate shall not be retroactive and shall only apply for conversions of Series B Convertible Preferred Stock followingthe date of any Dilutive Adjustment. The Conversion Rate is fixed at the time of Stockholder Approval and is not subject to further adjustmentthereafter. The Conversion Rate is designed to result in the holders of the Series B Convertible Preferred Stock receiving 40% of thethen outstanding shares of common stock upon conversion of the Series B Convertible Preferred Stock (66.7% of the Company’s pre-issuanceoutstanding shares of common stock), subject to a maximum of 10 million shares of common stock, and further subject to such conversionratio being fixed upon Stockholder Approval. The Conversion Rate is 1.318 or 1,318,000 total shares of common stock in aggregate as ofthe date of this prospectus.

Redemption Rights.None.

Stock Exchange Listing

Our common stock is currentlylisted on Nasdaq under the symbol “ATNF”.

Stock Exchange Listing

The transfer agent and registrarfor our common stock is Continental Stock Transfer & Trust Company.

Certain Anti-Takeover Provisions of DelawareLaw and our Certificate of Incorporation and Bylaws

We are subject to the provisionsof Section 203 of the Delaware General Corporation Law (the “DGCL”) regulating corporate takeovers. This statute preventscertain Delaware corporations, under certain circumstances, from engaging in a “business combination” with:

A “business combination”includes a merger or sale of more than 10% of our assets. However, the above provisions of Section 203 do not apply if:

Our Certificate of Incorporationprovides that our Board of Directors be classified into two classes of directors. As a result, in most circumstances, a person can gaincontrol of our Board of Directors only by successfully engaging in a proxy contest at two or more annual meetings.

Our authorized but unissuedcommon stock and preferred stock are available for future issuances without stockholder approval and could be utilized for a variety ofcorporate purposes, including future offerings to raise additional capital, acquisitions and employee benefit plans. The existence ofauthorized but unissued and unreserved common stock and preferred stock could render more difficult or discourage an attempt to obtaincontrol of us by means of a proxy contest, tender offer, merger or otherwise.

Securities Eligible for Future Sale

Rule 144

Pursuant to Rule 144, a personwho has beneficially owned restricted shares of our common stock or warrants for at least six months would be entitled to sell their securitiesprovided that (i) such person is not deemed to have been one of our affiliates at the time of, or at any time during the three monthspreceding, a sale and (ii) we are subject to the Exchange Act periodic reporting requirements for at least three months before thesale and have filed all required reports under Section 13 or 15(d) of the Exchange Act during the 12 months (or such shorter periodas we were required to file reports) preceding the sale.

Persons who have beneficiallyowned restricted shares of our common stock or warrants for at least six months but who are our affiliates at the time of, or at any timeduring the three months preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sellwithin any three-month period only a number of securities that does not exceed the greater of:

Sales by our affiliates underRule 144 are also limited by manner of sale provisions and notice requirements and to the availability of current public information aboutus.

Restrictions on theUse of Rule 144 by Shell Companies or Former Shell Companies

Rule 144 is not availablefor the resale of securities initially issued by shell companies (other than business combination related shell companies) or issuersthat have been at any time previously a shell company. However, Rule 144 also includes an important exception to this prohibition if thefollowing conditions are met:

Legal Matters

The validity of the securitiesoffered by this prospectus have been passed upon for us by The Loev Law Firm, PC. David M. Loev, the President and sole owner of The LoevLaw Firm, PC, beneficially owns less than 1% of the outstanding shares of our common stock.

Experts

The consolidated financialstatements of 180 Life Sciences Corp. and subsidiaries as of December 31, 2023 and 2022, and for each of the years in the two-year periodended December 31, 2023, are incorporated into this prospectus by reference from 180 Life Science Corp.’s Annual Report on Form10-K for the year ended December 31, 2023, have been audited by Marcum LLP, an independent registered public accounting firm, as set forthin their report thereon, incorporated herein by reference, and have been incorporated in this prospectus and Registration Statement inreliance upon such reports given on the authority of such firm as an expert in accounting and auditing.

No expert or counsel namedin this prospectus as having prepared or certified any part of this prospectus or having given an opinion upon the validity of the securitiesbeing registered or upon other legal matters in connection with the registration or offering of the common stock was employed on a contingencybasis, or had, or is to receive, any interest, directly or indirectly, in our Company or any of our parents or subsidiaries, nor was anysuch person connected with us or any of our parents or subsidiaries, if any, as a promoter, managing or principal underwriter, votingtrustee, director, officer, or employee.

Where You Can FindMore Information

We file annual, quarterlyand current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internetat the SEC’s website at http://www.sec.gov. Copies of certain information filed by us with the SEC are also available, free of charge,on our website at www.180lifesciences.com. Our website is not a part of this prospectus and is not incorporated by reference in this prospectus.

This prospectus is part ofa registration statement that we filed with the SEC. This prospectus omits some information contained in the registration statement inaccordance with SEC rules and regulations. You should review the information and exhibits in the registration statement for further informationabout us and our subsidiaries and the securities we are offering. Statements in this prospectus concerning any document we filed as anexhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified byreference to these filings. You should review the complete document to evaluate these statements. 

PART II
INFORMATION NOT REQUIRED IN PROSPECTUS

Item 13. Other Expenses of Issuance and Distribution.

The following table sets forthall expenses, other than the underwriting discounts and commissions, payable by the registrant in connection with the sale of the commonstock being registered. All the amounts shown are estimates except the SEC registration fee.

Item 14. Indemnification of Directors and Officers.

Section 145 of the DGCL authorizesa court to award, or a corporation’s board of directors to grant, indemnity to directors and officers in terms sufficiently broadto permit such indemnification under certain circumstances for liabilities, including reimbursement for expenses incurred, arising underthe Securities Act.

Our Certificate of Incorporationprovides for indemnification of our directors, officers, employees and other agents to the maximum extent permitted by the DGCL, and ourbylaws provide for indemnification of our directors, officers, employees and other agents to the maximum extent permitted by the DGCL.

In addition, we have enteredinto indemnification agreements with directors, officers and some employees containing provisions that are in some respects broader thanthe specific indemnification provisions contained in the DGCL. The indemnification agreements will require us, among other things, toindemnify our directors against certain liabilities that may arise by reason of their status or service as directors and to advance theirexpenses incurred as a result of any proceeding against them as to which they could be indemnified.

Item 15. Recent Sales of Unregistered Securities.

On April 5, 2023, we enteredinto a placement agent agreement with A.G.P. On April 5, 2023, in connection with the placement agent agreement, we also entered intoa securities purchase agreement pursuant to which we issued and sold, in a private placement, warrants to purchase up to 82,668 sharesof our common stock at a purchase price per share of $36.29 (when including shares of common stock and pre-funded warrants to purchaseshares of common stock in a registered direct offering) in the concurrent private placement. The offering closed on April 10, 2023.The net proceeds to us from the offering was approximately $2.7 million, after deducting placement agent fees and expenses and estimatedoffering expenses payable by us. We issued the warrants to purchase up to 82,668 shares of our common stock without registration underthe Securities Act, based on the exemption from registration afforded by Section 4(a)(2) thereof and/or Rule 506(b) of RegulationD promulgated thereunder.

On November 28, 2023, theCompany entered into Amendment No. 1 to the August SPA with a certain institutional investor (the “Purchaser”)(the“December 2023 SPA Amendment”), pursuant to which (i) the Purchaser agreed to pay an additional $830,769.30 in connectionwith the repricing of the August 2023 Shares and August 2023 Pre-Funded Warrants (the “Repricing Amount”), (ii) theCompany agreed to issue to the Purchaser (x) pre-funded warrants to purchase up to 257,205 shares of common stock, with an exercise priceof $0.0001 per share (the “December 2023 Pre-Funded Warrants”), and (y) warrants to purchase up to 477,058 shares ofcommon stock, with an exercise price of $0.17 per share (the “December 2023 Common Warrants” and, together with theDecember 2023 Pre-Funded Warrants, the “December 2023 Warrants”), and (iii) the Company and the Purchaser agreed toenter into the Warrant Amendment Agreement.

In accordance with the December2023 SPA Amendment, the Company entered into a warrant amendment agreement with the Purchaser, dated November 28, 2023 (the “December2023 Warrant Amendment Agreement”), whereby the Company agreed to amend the following outstanding warrants held by the Purchaser:(i) warrants to purchase up to 135,339 shares of common stock, issued on December 22, 2022, and amended in January 2023, April 2023 andAugust 2023; (ii) warrants to purchase up to 16,138 shares of common stock, issued on July 20, 2022 and amended in April 2023 and August2023; (iii) warrants to purchase up to 82,668 shares of common stock, issued on April 10, 2023 and August 2023; and (iv) warrantsto purchase up to 242,915 shares of common stock underlying the August Common Warrants (collectively, the “Existing Common Warrants”).Pursuant to the Warrant Amendment Agreement, the Existing Common Warrants were amended (the “December 2023 Warrant Amendment”)to not be exercisable until the Company obtained stockholder approval for the issuance of up to 477,058 shares of common stock upon exerciseof the Existing Common Warrants (the “Existing Common Warrant Shares”), which stockholder approval was received onFebruary 16, 2024. Pursuant to the December 2023 Warrant Agreement, the Existing Common Warrants were amended to have an exercise priceof $3.23 per share, and to expire on the fifth anniversary of the date that the stockholders of the Company approved the issuance of sharesof common stock upon exercise of such Existing Common Warrants, which stockholder approval date, which was February 16, 2024.

The warrants and the warrantshares have not been registered under the Securities Act, and were instead offered pursuant to the exemption provided in Section 4(a)(2)under the Securities Act.

On February 21, 2024, February28, 2024, March 6, 2024 and March 7, 2024, the holder of pre-funded warrants to purchase shares of common stock of the Company at an exerciseprice of $0.0019 per share, exercised warrants to purchase 58,520, 64,684, 72,000 and 62,000 shares of common stock, respectively, for$111.19, $122.90, $136.80 and $117.80 of cash, respectively, and was issued 58,520, 64,684, 72,000 and 62,000 shares of common stock uponexercise thereof, respectively. The exercise of the warrants was exempt from registration pursuant to Section 4(a)(2) of the SecuritiesAct.

On March 12, 2024, a holderof Class K Special Voting Shares converted such shares into 14 shares of common stock of the Company in a transaction exempt from registrationpursuant to Section 3(a)(9) of the Securities Act. As a result of such conversion, there are no longer any Class K Special Voting Shares.

On September 30, 2024, weclosed the transactions contemplated by that certain September 29, 2024, Asset Purchase Agreement (the “Purchase Agreement”) withElray Resources, Inc. (“Elray”), pursuant to which we acquired certain source code and intellectual property relatingto an online blockchain casino in consideration for 1,000,000 shares of newly designated Series B Convertible Preferred Stock (the “PreferredStock”) and warrants to purchase 3,000,000 shares of common stock of the Company (the “Warrants”). Theoffer and sale of the Preferred Stock and the Warrants were intended to be exempt from registration pursuant to Section 4(a)(2) and/orRule 506 of Regulation D of the Securities Act, since the foregoing offer, sales and issuances did not involve a public offering, therecipient confirmed that it was an “accredited investor”, and the recipient acquired the securities for investmentonly and not with a view towards, or for resale in connection with, the public sale or distribution thereof. The securities were offeredwithout any general solicitation by us or our representatives. The securities are subject to transfer restrictions, and the certificatesevidencing the securities will contain an appropriate legend stating that such securities have not been registered under the SecuritiesAct and may not be offered or sold absent registration or pursuant to an exemption therefrom.

OnOctober 17, 2024, the Company issued the Holder the October 2024 Warrants to purchase up to 1,900,138 shares of common stock with anexercise price of $1.50 per share pursuant to the terms of an Inducement Agreement dated October 16, 2024. The October 2024 Warrantswere immediately exercisable and have a term of exercise of five years. The Company claims an exemption from registration pursuant toSection 4(a)(2) and/or Rule 506 of the Securities Act for the issuance of the October 2024 Warrants since the foregoing issuance didnot involve a public offering, the recipient took the securities for investment and not resale, we took appropriate measures to restricttransfer, and the recipient was an accredited investor. The securities are subject to transfer restrictions, and the securities containan appropriate legend stating that such securities have not been registered under the Securities Act and may not be offered or sold absentregistration or pursuant to an exemption therefrom.

Item 16. Exhibits.

Item 17. Undertakings.

(a) The undersigned registrant hereby undertakes:

(1) To file, duringany period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i) To include any prospectusrequired by Section 10(a)(3) of the Securities Act;

(ii) To reflect in theprospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendmentthereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registrationstatement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securitiesoffered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offeringrange may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changesin volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculationof Registration Fee” table in the effective registration statement;

(iii) To include anymaterial information with respect to the plan of distribution not previously disclosed in the registration statement or any material changeto such information in the registration statement;

provided, however, that paragraphs(a)(1)(i), (a)(1)(ii) and (a)(1)(iii) above do not apply if the information required to be included in a post-effective amendmentby those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section15(d) of the Securities Exchange Act that are incorporated by reference in the registration statement, or is contained in a formof prospectus filed pursuant to Rule 424(b) that is part of the registration statement.

(2) That, for the purposeof determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statementrelating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fideoffering thereof.

(3) To remove from registrationby means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(4) That, for the purposeof determining liability under the Securities Act to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registrationstatement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in relianceon Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however,that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporatedor deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, asto a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registrationstatement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of firstuse.

(5) The undersigned registranthereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant's annualreport pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employeebenefit plan's annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in theregistration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offeringof such securities at that time shall be deemed to be the initial bona fide offering thereof.

(6) Insofar as indemnificationfor liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuantto the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is againstpublic policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities(other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrantin the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connectionwith the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controllingprecedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy asexpressed in the Securities Act and will be governed by the final adjudication of such issue.

SIGNATURES

Pursuant to the requirementsof the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned,thereunto duly authorized in the City of Palo Alto, State of California, on November 15, 2024.

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESEPRESENTS, that the persons whose signature appears below constitute and appoint Blair Jordan and Omar Jimenez, and each of them, as trueand lawful attorneys-in-fact and agents, with full powers of substitution and resubstitution, for them and in their name, place and stead,in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement (or anyregistration statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933),and to file the same, with all exhibits thereto, and other documents in connection therewith, with the SEC, and generally to do all suchthings in their names and behalf in their capacities as officers and directors to enable 180 Life Sciences Corp. to comply with the provisionsof the Securities Act of 1933 and all requirements of the SEC, granting unto said attorneys-in-fact and agents, and each of them, fullpower and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fullyto all intents and purposes as he might or could do in person, ratifying and confirming all that said attorneys-in-fact and agents, orany of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirementsof the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities indicated.